Immune cell landscape and immunotherapy of medulloblastoma
J Zhang, T Wang - Pediatric investigation, 2021 - mednexus.org
Medulloblastoma is the most common primary pediatric malignancy of the central nervous
system. Recurrent and refractory patients account for approximately 30% of them. Immune …
system. Recurrent and refractory patients account for approximately 30% of them. Immune …
Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma
JF Vermeulen, W Van Hecke, EJM Adriaansen… - …, 2018 - Taylor & Francis
Pediatric medulloblastomas are the most frequently diagnosed embryonal tumors of the
central nervous system. Current therapies cause severe neurological and cognitive side …
central nervous system. Current therapies cause severe neurological and cognitive side …
Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma
T Eisemann, RJ Wechsler-Reya - Genes & Development, 2022 - genesdev.cshlp.org
Medulloblastoma is an aggressive brain tumor that occurs predominantly in children.
Despite intensive therapy, many patients die of the disease, and novel therapies are …
Despite intensive therapy, many patients die of the disease, and novel therapies are …
Spotlighting cellular therapies to advance the treatment of medulloblastoma
JA Ligon, EJ Sayour - Neuro-oncology, 2023 - academic.oup.com
Medulloblastoma is the most common malignant brain tumor in pediatric patients and
conventional treatment can result in devastating long-term sequalae. 1–3This highlights the …
conventional treatment can result in devastating long-term sequalae. 1–3This highlights the …
Immunosuppression in medulloblastoma: insights into cancer immunity and immunotherapy
Opinion statement Medulloblastoma (MB) is the most common pediatric brain malignancy,
with a 5-year overall survival (OS) rate of around 65%. The conventional MB treatment …
with a 5-year overall survival (OS) rate of around 65%. The conventional MB treatment …
Immunotherapy for medulloblastoma: current perspectives
TF Kabir, CA Kunos, JL Villano… - ImmunoTargets and …, 2020 - Taylor & Francis
Background Immune-mediated therapies have transformed the treatment of metastatic
melanoma and renal, bladder, and both small and non-small cell lung carcinomas …
melanoma and renal, bladder, and both small and non-small cell lung carcinomas …
[HTML][HTML] Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors
Medulloblastoma (MB) is considered the commonest malignant brain tumor in children.
Multimodal treatments consisting of surgery, radiation, and chemotherapy have improved …
Multimodal treatments consisting of surgery, radiation, and chemotherapy have improved …
Immunotherapy in medulloblastoma: current state of research, challenges, and future perspectives
MJ Voskamp, S Li, KR van Daalen, S Crnko… - Cancers, 2021 - mdpi.com
Simple Summary Medulloblastoma (MB) is a primary brain tumor and is one of the most
prevalent neoplasms in the pediatric age group, with a median age of diagnosis of six years …
prevalent neoplasms in the pediatric age group, with a median age of diagnosis of six years …
Cellular immunotherapy for medulloblastoma
MY Schakelaar, M Monnikhof, S Crnko… - Neuro …, 2023 - academic.oup.com
Medulloblastoma (MB) is the most common malignant brain tumor in children, making up~
20% of all primary pediatric brain tumors. Current therapies consist of maximal surgical …
20% of all primary pediatric brain tumors. Current therapies consist of maximal surgical …
Medulloblasoma: challenges for effective immunotherapy
AM Sonabend, AT Ogden, LM Maier… - Journal of neuro …, 2012 - Springer
For medulloblastoma patients, the current therapeutic paradigm of surgery followed by
radiation and chemotherapy can lead to long-term remission. However, the sequelae of …
radiation and chemotherapy can lead to long-term remission. However, the sequelae of …